Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02076022 · ClinicalTrials.gov registry record · NA

AMP30: Autologous Fat Grafting, Amputation Sites Pain: Randomized

A NA study of Amputation and Wounded Warrior, sponsored by J. Peter Rubin, MD.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT02076022 is a NA study of Amputation and Wounded Warrior that has completed, run by J. Peter Rubin, MD. The registered enrollment target is 10 participants, below the 133-participant average among 65 other Amputation trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02076022, a NA study of Amputation and Wounded Warrior, has completed, sponsored by J. Peter Rubin, MD.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

We propose a prospective, randomized clinical study to assess the efficacy of minimally invasive autologous fat transfer addressing pain and poor prosthetic fit at amputation sites.

Interventions

  • DEVICE Enhanced Fat Grafting
  • PROCEDURE Standard fat graft

Study Locations (1)

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2014-04-08
Est. Completion 2019-01-28
Phase NA

Sponsor

J. Peter Rubin, MD

4 total trials

What the Registry Record Tells You About NCT02076022

The ClinicalTrials.gov registry entry for NCT02076022 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 65 other Amputation trials with a reported enrollment target (92% lower). The listed sponsor is J. Peter Rubin, MD, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Amputation appearing as the primary indexed condition, and to 2 interventions - of which Enhanced Fat Grafting is the first listed.

NCT02076022 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02076022 about?

NCT02076022 is a clinical study titled "AMP30: Autologous Fat Grafting, Amputation Sites Pain: Randomized". We propose a prospective, randomized clinical study to assess the efficacy of minimally invasive autologous fat transfer addressing pain and poor prosthetic fit at amputation sites.

What is the current status of trial NCT02076022?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2014-04-08. Estimated completion is 2019-01-28.

What conditions does trial NCT02076022 study?

This clinical trial studies the following conditions: Amputation, Wounded Warrior, Limb Shortening.

What interventions are being tested in trial NCT02076022?

The interventions under investigation include: Enhanced Fat Grafting (DEVICE), Standard fat graft (PROCEDURE).

Who is sponsoring clinical trial NCT02076022?

This trial is sponsored by J. Peter Rubin, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02076022 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amputation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.